Andrew R. Jordan - Jan 6, 2023 Form 4 Insider Report for IDERA PHARMACEUTICALS, INC. (IDRA)

Role
CHIEF STRATEGY OFFICER
Signature
/s/ John J. Kirby, Attorney-in-Fact
Stock symbol
IDRA
Transactions as of
Jan 6, 2023
Transactions value $
-$52,490
Form type
4
Date filed
1/10/2023, 08:19 PM
Previous filing
Sep 30, 2022
Next filing
Jan 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDRA Common Stock Award $0 +262K +40.18% $0.00 913K Jan 6, 2023 Direct F1
transaction IDRA Common Stock Tax liability -$52.5K -73.9K -8.1% $0.71 839K Jan 6, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock granted under the Idera Pharmaceuticals, Inc. 2013 Stock Incentive Plan, as amended and restated. The shares were granted pursuant to that certain Employment Continuation and Retention Bonus Letter Agreement, dated as of September 28, 2022, between the Issuer and Reporting Person.
F2 Represents the number of shares withheld by Issuer to cover tax obligations in connection with the grant of the shares of common stock.